Characteristics and Financial Implications of Measures Removed From Medicare Advantage Star Ratings

• by Derek T. Lake, Yasin Civelek, Amelia M. Bond, Dhruv Khullar

• October 23, 2026

H2-blocker tachyphylaxis may limit LPR therapy

Acid suppression wanes rapidly with repeated dosing, supporting intermittent use and phenotype-directed evaluation of persistent symptoms.

• by Andrea Surnit

• October 23, 2026

• 4 min

The Evidence-Based Cancer Control Programs website – a strategy for disseminating effective interventions

• by Aubrey Villalobos, Jennifer Damonte, David A. Chambers

• October 23, 2026

Can Clinical Trials Collect Less Data Without Compromising Safety?

Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.

• by Mouj Hijazi

• October 22, 2026

• 8 min